Triferic’s ESA-Reduction Claim Draws FDA Skepticism Ahead Of ODAC Review

Rockwell’s iron replacement therapy could be hindered by absence of ESA-reduction claim even if drug makes it through FDA with more limited indication; agency will have to address its own discrepancies in briefing document data at the Nov. 6 Oncologic Drugs Advisory Committee.